We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.32 | -2.63% | 48.79 | 48.73 | 48.75 | 11,228 | 10:52:33 |
From Dec 2023 to Jun 2024
By Adria Calatayud
Sanofi appointed Brian Foard, who has helmed the launch of its blockbuster anti-inflammatory drug Dupixent, as permanent head of its specialty-care business unit and member of its executive committee.
Foard, who has more than 20 years of experience in the industry, has been interim head of the unit since September while also serving as head of specialty care in North America and U.S. country lead, the French pharmaceutical company said Tuesday.
He joined the company in 2017 and began his career with Galderma, Sanofi said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
January 09, 2024 01:59 ET (06:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
